Mesoblast Limited (MESO) vs Vericel Corporation (VCEL)
Mesoblast Limited and Vericel Corporation are both Biotechnology companies. Mesoblast Limited and Vericel Corporation are of similar size ($2.0B and $2.0B). Mesoblast Limited has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 82.6×. Vericel Corporation grew revenue faster over the last twelve months: 23.0% against −26.5%. Vericel Corporation has the higher net margin (7.91% vs −1,091.7%) and the higher return on invested capital (5.49% vs 0.00%). Across the 19 metrics below, Vericel Corporation leads on 17 and Mesoblast Limited on 2.
Valuation
Profitability
| Metric | MESO | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 74.56% | 65.16% |
| Operating margin | (826.28%) | 5.95% | 0.00% |
| Net margin | (1,091.71%) | 7.91% | 0.00% |
| Free cash flow margin | 0.00% | 20.13% | 0.00% |
| Return on equity | 0.00% | 7.16% | (57.72%) |
| Return on assets | 0.00% | 5.16% | (49.22%) |
| Return on invested capital | 0.00% | 5.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack